Management of sexual dysfunction after prostate brachytherapy

Area of Science:

• Urology
• Oncology
• Radiation Oncology

Background:

• Erectile dysfunction (ED) is a frequent complication after prostate cancer treatment.
• Prostate brachytherapy, a local radiation therapy, is associated with a higher incidence of ED than previously recognized.
• Several factors can worsen ED post-brachytherapy.

Purpose of the Study:

• To investigate the incidence and contributing factors of erectile dysfunction following prostate brachytherapy.
• To assess the efficacy of sildenafil citrate in managing brachytherapy-induced ED.
• To explore potential improvements in treatment techniques for better potency preservation.

Main Methods:

• Analysis of patient data from larger studies with extended follow-up periods.
• Identification of risk factors associated with ED, including pre-treatment potency, age, and radiation parameters.
• Evaluation of treatment outcomes for patients receiving sildenafil citrate for ED.

Main Results:

• Approximately 50% of patients develop ED within 5 years of prostate brachytherapy.
• Pre-implant potency, patient age, external beam irradiation, radiation dose to the prostate and penile bulb, and diabetes mellitus are identified as exacerbating factors.
• The majority of patients with brachytherapy-induced ED show positive responses to sildenafil citrate.

Conclusions:

• Erectile dysfunction is a significant and common sequela of prostate brachytherapy.
• Understanding risk factors and treatment responses can lead to improved patient outcomes.
• Further refinement of brachytherapy techniques may enhance potency preservation and quality of life for prostate cancer survivors.